R193
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MITOTIC_SPINDLE+0.450
- G2M_CHECKPOINT+0.400
- INTERFERON_ALPHA_RESPONSE+0.380
- MYC_TARGETS_V2+0.360
- E2F_TARGETS+0.310
- PROTEIN_SECRETION+0.310
- MYC_TARGETS_V1+0.300
- TGF_BETA_SIGNALING+0.240
- UNFOLDED_PROTEIN_RESPONSE+0.240
- DNA_REPAIR+0.220
Top 10 suppressed
- ANGIOGENESIS-0.410
- KRAS_SIGNALING_DN-0.380
- HYPOXIA-0.330
- MYOGENESIS-0.310
- BILE_ACID_METABOLISM-0.290
- ESTROGEN_RESPONSE_LATE-0.290
- APICAL_SURFACE-0.280
- COAGULATION-0.280
- KRAS_SIGNALING_UP-0.280
- XENOBIOTIC_METABOLISM-0.280
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SJEPD031236_D1.RNA-Seq | EPN | Supratentorial EPN | 0.839 |
| 2 | SRR934887 | — | — | 0.814 |
| 3 | 65567450-e04a-4251-9939-8d2545077236 | — | — | 0.806 |
| 4 | MNG861 | — | — | 0.802 |
| 5 | 550c15f6-55cf-4928-bc62-bb28bc5672da | — | — | 0.797 |
| 6 | MNG573 | — | — | 0.794 |
| 7 | 8B2B5542-3E54-4643-BB57-0BEFCF89A16B | — | — | 0.793 |
| 8 | MNG274 | — | — | 0.784 |
| 9 | SRR8613807 | — | E | 0.781 |
| 10 | MNG951 | — | — | 0.772 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MITOTIC_SPINDLE | 0.450 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.400 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.380 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.360 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.310 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.310 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.300 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.240 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.240 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.220 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.220 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.180 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.170 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.170 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.090 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.020 | Temsirolimus | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.010 | Inavolisib | — uncovered |